SciELO - Scientific Electronic Library Online

 
vol.34 número4Perfil epidemiológico de las intoxicaciones por antidepresivos recibidas en el Centro Información y Asesoramiento Toxicológico uruguayo en el período 2010-2012Contaminación enteroparasitaria de moscas capturadas en el municipio Palavecino, estado Lara, Venezuela, 2017 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Médica del Uruguay

versión impresa ISSN 0303-3295versión On-line ISSN 1688-0390

Resumen

RANERO, Sabrina et al. Effectiveness of bortezomib treatment in patients with multiple myeloma at the Clínicas Hospitalbetween 2009 and 2016. Montevideo, Uruguay. Rev. Méd. Urug. [online]. 2018, vol.34, n.4, pp.48-69. ISSN 0303-3295.  http://dx.doi.org/10.29193/rmu.34.4.3.

Abstract:

Multiple mieloma represents the secon neoplasis in terms of frequency. It is an incurable disease, whose survival has doubled in recent years with the emergence of new drugs. Plan including bortezomib improve response, progression free survival and global survival. In Uruguay this drig is covered by the National Resources Find (FNR) since 2009. This study aims to analyse the experience of using bortezomib in patients with a diagnosis of multiple myeloma at the Clínicas Hospital.

Method:

observational, retrospective and descriptive study that included all patients with a diagnosis of multiple myeloma who received bortezomib treatment in the first, second and/or third line at the Clínicas Hospital of Montevideo; Uruguay from 2009 and 2016.

Results:

36 patients received bortezomib. The most frequently used plan was cyclophosphamide-bortezomib-dexamethasone, subcutaneously administered in 54% of cases. Global response rate was 79.5% (87% in the first line, 68.8% in the second or third line). 43.6% of patients developed polineuropahty and 28.2 % cytopenia. With a median follow up of 26 months, global survival was 61% and progression free survival was 35 months, (CI 95%, 22.6-47.4).

Conclusion:

bortezomib treatment achieved a good reponse rate. Neuropathy was the most frequent toxicity. Bortezomib is an effective drug and it has the adequate safety profile to treat MM in the first, second and third line.

Palabras clave : Multiple myeloma; Bortezomib; Treatment outcome.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )